All In Biotech

Drug Trial Radar · NCT05686096

A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435

A Phase 1, Open-label, Single Dose Study to Assess the Absorption, Metabolism, and Excretion of [14C]BMS-986435 in Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: May 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7

Actual

Start

Jan 16, 2023

Primary completion

Apr 8, 2023

Study completion Apr 8, 2023

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the absorption, metabolism, excretion; and to evaluate the safety and tolerability of BMS-986435 in healthy male participants Participants will be admitted to the study site for 3 weeks.

Conditions

  • Healthy Volunteers

Interventions

  • MYK-224Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed concentration (Cmax)Time frame: Up to 45 days
  2. Time to maximum observed concentration (Tmax)Time frame: Up to 45 days
  3. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))Time frame: Up to 45 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0001

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.